AVTR · Avantor, Inc. · Executive Compensation
$15.32
-0.22 (-1.42%)
At close · Nov 16
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$10.38B
Shares
677.62M
Volume · Nov 16
6.15M
Avg daily vol (3M)
8.63M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Michael Stubblefield | Former Chief Executive Officer | $13,077,931 |
| R. Brent Jones | Executive Vice President and Chief Financial Officer | $6,538,667 |
| Corey Walker | President Laboratory Solutions | $5,987,816 |
| Emmanuel Ligner | Director, President and Chief Executive Officer | $5,895,624 |
| Benoit Gourdier | Executive Vice President Bioscience Production | $5,225,419 |
| Claudius Sokenu | Executive Vice President, Chief Legal and Compliance Officer | $3,749,913 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Michael Stubblefield | Former Chief Executive Officer | $14,525,638 |
| R. Brent Jones | Executive Vice President and Chief Financial Officer | $3,886,451 |
| Benoit Gourdier | Executive Vice President Bioscience Production | $3,733,064 |
| Claudius Sokenu | Executive Vice President, Chief Legal and Compliance Officer | $2,832,857 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Michael Stubblefield | Director, President and Chief Executive Officer | $12,338,767 |
| R. Brent Jones | Executive Vice President and Chief Financial Officer | $5,840,795 |
| Randy Stone | Executive Vice President | $4,588,116 |
| Frederic Vanderhaegen | Executive Vice President Europe | $3,043,353 |
| Gerard Brophy | Former Executive Vice President, | $2,907,627 |
| Thomas Szlosek | Former Executive Vice President and Chief Financial Officer | $2,882,892 |
| James Bramwell | Executive Vice President, Americas | $2,840,235 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Michael Stubblefield | Director, President and Chief Executive Officer | $10,831,766 |
| Thomas Szlosek | Former Executive Vice President and Chief Financial Officer | $2,923,808 |
| Frederic Vanderhaegen | Executive Vice President Europe | $2,760,151 |
| Gerard Brophy | Former Executive Vice President, | $2,676,620 |
| Sheri Lewis | Executive Vice President, Global Operations & Supply Chain | $1,851,744 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Michael Stubblefield | Director, President and Chief Executive Officer | $13,260,913 |
| Thomas Szlosek | Former Executive Vice President and Chief Financial Officer | $4,335,943 |
| Frederic Vanderhaegen | Executive Vice President Europe | $3,565,108 |
| Gerard Brophy | Executive Vice President | $3,338,920 |
| Biopharma Production | — | $3,338,920 |
| Sheri Lewis | Executive Vice President, Global Operations & Supply Chain | $2,913,973 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Michael Stubblefield | Director, President and Chief Executive Officer | $11,257,062 |
| Thomas Szlosek | Executive Vice President and Chief Financial Officer | $6,243,778 |
| Frederic Vanderhaegen | Executive Vice President Europe | $4,638,011 |
| Biopharma Production | — | $4,278,996 |
| Gerard Brophy | Executive Vice President | $4,278,996 |
| Michael Wondrasch | Executive Vice President,Chief Information Officer | $3,192,367 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Michael Stubblefield | Director, President and Chief Executive Officer | $16,995,265 |
| Ashish Kulkarni | Executive Vice President and Chief Technology Officer | $5,068,233 |
| Thomas Szlosek | Executive Vice President and Chief FinancialOfficer | $3,977,065 |
| Devashish Ohri | Executive Vice President, IMEA | $3,292,319 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Todd Garner | Executive Vice President and Chief Financial Officer | Appointed | 2026-09-21 |
| Todd Garner | Executive Vice President and Chief Financial Officer | Appointed | 2026-09-21 |
| Ludovic Brellier | Executive Vice President, Bioscience and Medtech Products and Chief Transformation Officer | Appointed | 2026-04-23 |
| R. Brent Jones | Executive Vice President and Chief Financial Officer | Resigned | 2026-04-01 |
| Jonathan Peacock | director | Resigned | 2025-12-18 |
| Simon Dingemans | director | Appointed | 2025-12-18 |
| Sanjeev Mehra | director | Appointed | 2025-12-04 |
| Mary Blenn | Executive Vice President and Chief Operating Officer | Appointed | 2025-11-10 |
| Gregory L. Summe | chairman | Appointed | 2025-10-14 |
| Gregory Lucier | director | Appointed | 2025-10-03 |
| Emmanuel Ligner | director | Appointed | 2025-08-13 |
| Emmanuel Ligner | President and Chief Executive Officer | Appointed | 2025-07-21 |
| Dame Louise Makin DBE | director | Appointed | 2024-11-06 |
| Corey Walker | President, Laboratory Solutions | Appointed | 2024-06-21 |
| Randy Stone | Executive Vice President, Laboratory Solutions | Terminated | 2024-06-21 |
| Dr. Gerard Brophy | Executive Vice President, Biopharma Production | Retired | 2023-09-26 |
| Dr. Gerard Brophy | Executive Vice President, Biopharma Production | Resigned | 2023-09-26 |
| R. Brent Jones | Executive Vice President and Chief Financial Officer | Appointed | 2023-07-13 |
| Thomas A. Szlosek | Executive Vice President and Chief Financial Officer | Resigned | 2023-05-15 |
| Matt Holt | Board of Directors | Retired | 2022-11-18 |
Leadership
- Michael Stubblefield CEO
- Gregory L. Summe Chairman
- R. Brent Jones CFO
- Thomas Szlosek CFO
- Todd Garner CFO
- Bjorn Hofman COO
- Mary Blenn COO
- Ashish Kulkarni CTO
- Michael Wondrasch CIO
- Dame Louise Makin Board Member
- Dame Louise Makin DBE Board Member
- Emmanuel Ligner Board Member
- Gregory Lucier Board Member
- Gregory Summe Board Member
- John Carethers, M.D. Board Member
- Joseph Massaro Board Member
- Louise Makin Board Member
- Mala Murthy Board Member
- Michael Severino Board Member
- Sanjeev Mehra Board Member
- Simon Dingemans Board Member
Key facts
CIK
1722482
CUSIP
05352A100
13F (30d)
414 filings
386 filers
Visit website
Investor relations